Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649862 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10DRD2 | |
| SCHEMBL1534864 | 0.77 | JAK2 (0.39) | KDM4EALDH1A1HPGDHSD17B10DRD2 | |
| SCHEMBL186269 | 0.72 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10DRD2 | |
| SCHEMBL29593052 | 0.71 | TSHR (0.39) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL7164061 | 0.71 | TSHR (0.39) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL28805039 | 0.70 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Cyanide SCHEMBL28871133 | 0.68 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDHSD17B10DRD2 | |
| SCHEMBL3838085 | 0.68 | KDM4E (0.33) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16517725 | 0.67 | — | — | |
| SCHEMBL19062287 | 0.66 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHSD17B10DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | claimed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | claimed |
| EP-0986541-A4 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMW SCIENT IND RES ORG (AU) | 2002-08-14 | — | — | EP | claimed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | claimed |
| EP-0986541-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-22 | — | — | EP | claimed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | KDM4E 884/4885ALDH1A1 1148/4885HPGD 4463/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | KDM4E 212/4885ALDH1A1 968/4885HPGD 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.